Proficio Capital Partners LLC Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Proficio Capital Partners LLC bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) during the fourth quarter, Holdings Channel.com reports. The fund bought 25,271 shares of the company’s stock, valued at approximately $1,353,000.

Other large investors have also recently bought and sold shares of the company. Avanza Fonder AB acquired a new stake in Janux Therapeutics in the 4th quarter worth $139,000. Chicago Capital LLC acquired a new stake in Janux Therapeutics during the fourth quarter worth about $230,000. Y Intercept Hong Kong Ltd bought a new position in Janux Therapeutics during the third quarter valued at about $317,000. Virtu Financial LLC raised its holdings in Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares in the last quarter. Finally, Legato Capital Management LLC bought a new stake in shares of Janux Therapeutics in the 4th quarter worth approximately $347,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Stock Down 1.6 %

NASDAQ:JANX opened at $30.43 on Friday. The firm has a market cap of $1.80 billion, a PE ratio of -26.01 and a beta of 3.23. The company’s 50-day moving average price is $37.22 and its two-hundred day moving average price is $46.56. Janux Therapeutics, Inc. has a 12 month low of $28.92 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. On average, research analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on JANX shares. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Wedbush reaffirmed an “outperform” rating and set a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $92.44.

Insider Activity at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the sale, the chief executive officer now directly owns 217,054 shares of the company’s stock, valued at approximately $12,196,264.26. This trade represents a 10.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were purchased at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares of the company’s stock, valued at $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 50,002 shares of company stock valued at $2,684,703 over the last ninety days. 29.40% of the stock is owned by insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.